0
Skip to Content
Global Kratom Coalition™
Global Kratom Coalition™
Advocacy
Restricted Zip Codes
Congressional Letter to FDA
GKC Letter to FDA
Leaf Kratom Regulation Map - USA
Louisiana Poll on Leaf Kratom Regulation
FDA’s Concentrated 7-OH Product Crackdown
Florida 7-OH Crackdown
KCAC's Advocacy Buddy
GKC For Consumers
The Evolution of Leaf Kratom Infographic
Marketing Guidelines
Florida FAQ Flyer
KCPA Label Requirement
Concentrated 7-OH Opioid Products Database
About Us
Tax Status
Contact Us
Sign Up To Our Email List
AHP Botanical Safety Handbook
Scientists' Statement
Safety
Relative Safety/Risk Report: Kratom vs. Other Substances
GKC Statement on 7-Hydroxymitragynine Products
Scientists Statement on 7-OH MGPI Products
SUD Report: Prevalence, Severity and Symptom Endorsement
The Severity and Prevalence of Addictive Substances
Kratom Alkaloids
FDA Study on Kratom Dosing and Safety
National Marketing Institute (NMI) Kratom Survey
UCONN Continuing Education Program
"7" Fact vs. Fiction
Eight-Factor Analysis of Natural Kratom Leaf
Rise in Poison Center Calls are From Concentrated 7-OH: Data
18 Human Clinical Trials
In the News
Advocacy Buddy
About KCAC
KCAC Board Members
KCAC Position Statements
KCAC In The News
UConn Pharmacy Research on Kratom and Substances of Abuse
KCAC 2025 Impact Snapshot
Eight-Factor Analysis of Natural Kratom Leaf
Stop Gas Station Heroin
Global Kratom Coalition™
Global Kratom Coalition™
Advocacy
Restricted Zip Codes
Congressional Letter to FDA
GKC Letter to FDA
Leaf Kratom Regulation Map - USA
Louisiana Poll on Leaf Kratom Regulation
FDA’s Concentrated 7-OH Product Crackdown
Florida 7-OH Crackdown
KCAC's Advocacy Buddy
GKC For Consumers
The Evolution of Leaf Kratom Infographic
Marketing Guidelines
Florida FAQ Flyer
KCPA Label Requirement
Concentrated 7-OH Opioid Products Database
About Us
Tax Status
Contact Us
Sign Up To Our Email List
AHP Botanical Safety Handbook
Scientists' Statement
Safety
Relative Safety/Risk Report: Kratom vs. Other Substances
GKC Statement on 7-Hydroxymitragynine Products
Scientists Statement on 7-OH MGPI Products
SUD Report: Prevalence, Severity and Symptom Endorsement
The Severity and Prevalence of Addictive Substances
Kratom Alkaloids
FDA Study on Kratom Dosing and Safety
National Marketing Institute (NMI) Kratom Survey
UCONN Continuing Education Program
"7" Fact vs. Fiction
Eight-Factor Analysis of Natural Kratom Leaf
Rise in Poison Center Calls are From Concentrated 7-OH: Data
18 Human Clinical Trials
In the News
Advocacy Buddy
About KCAC
KCAC Board Members
KCAC Position Statements
KCAC In The News
UConn Pharmacy Research on Kratom and Substances of Abuse
KCAC 2025 Impact Snapshot
Eight-Factor Analysis of Natural Kratom Leaf
Stop Gas Station Heroin
Folder: Advocacy
Back
Advocacy
Restricted Zip Codes
Congressional Letter to FDA
GKC Letter to FDA
Leaf Kratom Regulation Map - USA
Louisiana Poll on Leaf Kratom Regulation
FDA’s Concentrated 7-OH Product Crackdown
Florida 7-OH Crackdown
KCAC's Advocacy Buddy
Folder: Consumers
Back
GKC For Consumers
The Evolution of Leaf Kratom Infographic
Folder: Business
Back
Marketing Guidelines
Florida FAQ Flyer
KCPA Label Requirement
Concentrated 7-OH Opioid Products Database
Folder: About
Back
About Us
Tax Status
Contact Us
Sign Up To Our Email List
Folder: Health & Science
Back
AHP Botanical Safety Handbook
Scientists' Statement
Safety
Relative Safety/Risk Report: Kratom vs. Other Substances
GKC Statement on 7-Hydroxymitragynine Products
Scientists Statement on 7-OH MGPI Products
SUD Report: Prevalence, Severity and Symptom Endorsement
The Severity and Prevalence of Addictive Substances
Kratom Alkaloids
FDA Study on Kratom Dosing and Safety
National Marketing Institute (NMI) Kratom Survey
UCONN Continuing Education Program
"7" Fact vs. Fiction
Eight-Factor Analysis of Natural Kratom Leaf
Rise in Poison Center Calls are From Concentrated 7-OH: Data
18 Human Clinical Trials
Folder: Media
Back
In the News
Folder: KCAC
Back
Advocacy Buddy
About KCAC
KCAC Board Members
KCAC Position Statements
KCAC In The News
UConn Pharmacy Research on Kratom and Substances of Abuse
KCAC 2025 Impact Snapshot
Eight-Factor Analysis of Natural Kratom Leaf
Stop Gas Station Heroin
Peer-Reviewed Research

18 Human
Clinical Trials

Clinical Science Supporting Safe Use In Humans

⬡

Study 01

Safety and Tolerability Trial

View on PubMed ↗

Study 02

Pilot Dose-Finding PD/PK Trial

View on PubMed ↗

Study 03

Kava-Kratom Blend Safety

View on PubMed ↗

Study 04

Itraconazole Interaction PK

View on PubMed ↗

Study 05

Single and Multiple Dose PK

View on PubMed ↗

Study 06

Drug Interaction Potential

View on PubMed ↗

Study 07

Healthy Adult PK Assessment

View on PubMed ↗

Study 08

Cardiovascular Case Series

View on PubMed ↗

Study 09

ECG Abnormalities Study

View on PubMed ↗

Study 10

Pain Tolerance Trial

View on PubMed ↗

Study 11

Psychotic Symptoms Prevalence

View on PubMed ↗

Study 12

Long-Term Cognitive Effects

View on PubMed ↗

Study 13

Brain MRI Study

View Study ↗

Study 14

Psychological Withdrawal Severity

View on PubMed ↗

Study 15

Hormone Levels Study

View on PubMed ↗

Study 16

Hematology and Clinical Chemistry

View on PubMed ↗

Study 17

Mitragynine PK in Man

View on PubMed ↗

Study 18

Dependence, Withdrawal and Craving

View on PubMed ↗

All studies link to peer-reviewed publications. Global Kratom Coalition — Science-Based Advocacy.

FAQ

Research

Testimonials

Media

Contact Us

About Us

Privacy Policy

Terms of Service

2026 Global Kratom Coalition™

All Rights Reserved.